The call for meaningful patient and family engagement in research has recently gained considerable momentum. This article defines patient and family engagement broadly and specifically in clinical research. Using a multicenter, North American weaning trial as an exemplar, we describe our early experiences as clinical researchers with patient and family engagement. The role of our Patient and Family Advisory Committee in trial design and implementation is illustrated. Through our experiences, we share our insights regarding the perceived opportunities and also highlight some challenges associated with engaging patients and family engagement in critical care research. Although "engagement science" is in its infancy, engaging patients and families in research holds promise as a novel research paradigm that will not only provide new insights into the questions, methods, and outcomes used in ICU research, but it will also make investments in research more accountable and ensure a strong "patient-and family-centered focus" of our research.
The call for meaningful patient and family engagement in health care and research is gaining momentum. 1 Engagement focuses on the relationship between patients and health-care providers working together to promote and support active public involvement in health and health care and to strengthen the influence patients and families have on the care decisions that affect them. 2 Although public engagement is a laudable goal, it is not a simple matter. 3 This reform requires that stakeholders in healthcare delivery and research (including patients, families, health-care and research organizations, communities, and government) work closely together to advance patient care and research.
Patient and family engagement in research is a relatively new concept. Most engagement work in critical care research has focused on establishing research priorities and has been conducted from the perspective of investigators, funding organizations, and institutions. In the context of stakeholder priority-setting meetings, participants (including patient and family representatives) work together with investigators to identify and prioritize uncertainties and formulate research questions into a formal research agenda. [4] [5] [6] [7] [8] [9] National and international guidance documents support the importance of patient and family engagement in research. 10, 11 Patient and family members can also be engaged in clinical research in real time by collaborating in the design, implementation, governance, and dissemination of research. 14 Although most critically ill patients undergo some form of weaning, "best evidence" was generated nearly 2 decades ago and is of questionable relevance to current ICU practice. [15] [16] [17] Specifically, although a metaanalysis and clinical practice guideline support oncedaily screening, most weaning evidence was published before daily screening became commonplace. 18, 19 Notwithstanding, once-daily screening is poorly aligned with around-the-clock continuous care provided in most ICUs today. Moreover, considerable uncertainty exists regarding the best SBT technique to use to evaluate patients' ability to breathe spontaneously and maximize their chance of being successfully extubated. [20] [21] [22] The around-the-clock presence of respiratory therapists in North American ICUs presents a unique opportunity to identify the best weaning strategy (both screening frequency and SBT technique) for clinicians to use to liberate critically ill patients from invasive ventilation.
The design of the FAST trial was informed by conduct of a multicenter, pilot, factorial design trial. 23 The pilot trial was designed to assess feasibility metrics, including the ability to recruit the desired population and for clinicians to implement the screening and SBT protocols as designed with minimal protocol violations and adverse events. The large-scale FAST trial is a multicenter, factorial design randomized controlled trial comparing both screening frequency (once-daily vs at least twice-daily screening) and SBT technique (pressure support vs T-piece) in 760 critically ill adults in 20 ICUs in Canada and the United States.
Role of the Patient and Family Advisory Committee
A highly innovative component of the FAST trial is the integration of ICU survivors and family members into a Patient and Family Advisory Committee (PFAC). The PFAC comprises five ICU survivors and family members with unique perspectives on critical illness and mechanical ventilation experiences. The PFAC includes three ICU survivors (two from Canada, one from the United States) and two family members (one from Canada and one from the United States). As integral members of the research team, the PFAC serves in an advisory capacity to the trial Steering Committee. In addition, one PFAC member serves as a member of the trial Steering Committee and another on the Data and Safety Monitoring Committee (Fig 1) .
Since August 2015, PFAC members have engaged in discussions with the investigators related to the largescale FAST trial design. Working with the Steering Committee, the five-member PFAC assisted the investigators with selecting trial outcomes and preparing grant submissions. In designing the protocol, PFAC members played a prominent role in identifying and refining primary and secondary outcomes. For example, in early drafts of the trial protocol, the clinical investigators had selected "time to successful SBT completion" as the primary trial outcome. The rationale for this choice was that "time to successful SBT completion" was clinically important, could be objectively measured, and directly reflected the interventions being evaluated in the FAST trial. However, in discussions over electronic mail, with PFAC members, we began to question whether this outcome was in fact important to patients and families.
To inform this discussion and to better understand general and ventilation-specific outcomes that are important to members of the general public (sampling frame), we conducted an interviewer-administered questionnaire of 322 visitors (sampling element) in adult ICU waiting rooms in parallel with grant preparation. Using survey methods, we identified two general outcomes (ICU and hospital survival) and three ventilation-related outcomes (being ventilator free, avoiding reintubation, and passing a spontaneous breathing trial) that were rated highly by respondents. ICU visitors also rated other outcomes highly, including avoiding complications (pneumonia and bloodstream infections), maintaining quality of life, ensuring patient comfort, and the ability to return to previous living arrangements. 24 Based on the results of this questionnaire and through discussions with our PFAC, we changed the primary outcome of the FAST trial from "time to successful SBT completion" to "time to successful extubation."
With experiences in recovery and rehabilitation being particularly salient for ICU survivors, we also added a nested 6-month follow-up study to evaluate participant's health-related quality of life and functional status 6 months after randomization. During grant preparation, one family member reviewed key components of the trial protocol and provided written comments to ensure that it was easy to read and would be understood by any member of the general public serving on grant review committees. Moving forward, PFAC members will directly advise the Steering Committee on study design and implementation issues that are important to them during trial implementation. Members of the PFAC will aid in preparing study materials (eg, consent forms, brochures regarding weaning and trial participation) to ensure that they are easy for family members to read and understand. They will also review and assist the Steering Committee in selecting a metric to assess functional status (either the Impact Event Scale revised, 25 Lawton ) at the 6-month follow-up assessments. PFAC members will participate in teleconferences every other month to deliberate and resolve issues as they arise during trial implementation. For their engagement and to enhance their understanding of research, PFAC members will be paid for their time and will be invited to attend either a research consortium meeting or an international scientific meeting. 13 During and after trial implementation, members of the PFAC will contribute to developing a moderated online space that will serve as a repository for patient and family narratives. PFAC members will aid in preparing and share in authoring publications (eg, posters and manuscripts) arising from the large-scale FAST trial, including a protocol manuscript, results of the factorial randomized controlled trial, and the nested follow-up study. PFAC members will also assist in disseminating new knowledge gained from the trial by preparing trial summaries for lay audiences and through oral presentations at various venues.
Insights Into the Engagement Process in Clinical Research
Through our initial experiences with patient and family engagement in designing and implementing a clinical trial, we have not only developed new expertise but also gained valuable insights into the opportunities and challenges associated with engaging these key ICU stakeholders. First, our experience underscores that patients and family members can contribute in important and meaningful ways to research design. Second, we note that early and structured involvement of patient and family representatives affords the greatest opportunity for their input to meaningfully affect trial design. Funding constraints, however, may be an important and underappreciated impediment to early engagement. [28] [29] [30] Third, the ways in which investigators can engage patients and family members in trial design, implementation, and knowledge dissemination is unlimited, constrained only by the creativity of the investigative team. Fourth, sparse literature exists to address the unique challenges inherent in selecting and engaging ICU survivors and family members in research, and no literature exists to address potential sources of bias (eg, selection, recall and interpretation bias, self-improvement effect) that may arise during engagement. The method behind how to engage patients and families in different aspects of research and how to sustain and optimize their engagement remain to be elucidated. Additional investigations are required to characterize facilitators of and barriers to research engagement. Moreover, the psychological risks to patients and families, related to reflecting on their ICU stay, and the risk to the physician-patient relationship and health-care system remain to be delineated. 3, [31] [32] [33] Fifth, engagement requires additional time and effort and a shared commitment to work together. As with any successful partnership, the relationship ascribes equal value to all opinions and is based on mutual respect, shared goals, and a shared belief that the activity is important. In this regard, tokenistic engagement practices devalue and undermine the intent of the engagement process and may impede investigators' ability to appreciate the true impact that meaningful engagement can have on the process. 30 Sixth, it is reasonable to compensate patients and relatives for their time and work; however, limited funding mechanisms, especially early in research design, may constrain the investigators' ability to remunerate participants. 28, 29 To this end, even small amounts of funding have been shown to favorably influence participant engagement. 31, 34 Finally, although engagement activities may have intrinsic merit as a socially constructed process, additional data are required to fully assess their impact on process-related findings and other outcomes. The science behind patient and family engagement remains to be developed and empirically evaluated.
Conclusions
"Research engagement" focuses on stakeholders and investigators working together to design, implement, and support the stakeholder (especially patient and family) involvement in the scientific process. Although the science behind engagement is in its infancy, and engagement activities may vary substantially, engaging ICU survivors and family in research holds promise as a novel research paradigm that will not only provide new insights into our research but also make investments into research more accountable and ensure a strong patient and family focus in our research.
